UNC LINEBERGER | Strategic Alliance Partners


Pevonedistat Shows Promising Partner Potential for HMAs in Higher-Risk MDS

August 03, 2021

Joshua F. Zeidner, MD, discusses the role that HMAs have played in the MDS treatment landscape and shared data reported with promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets.

Dr. Pecot on the Frontline Standard of Care in Squamous NSCLC

June 20, 2019

Chad Pecot, MD, assistant professor, Department of Medicine, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, discusses the frontline standard of care in advanced squamous non–small cell lung cancer (NSCLC).

Dr. Lee on Tailoring Treatment to Tumor Sidedness in mCRC

April 04, 2019

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment to tumor sidedness in patients with metastatic colorectal cancer.